<bill session="118" type="h" number="5547" updated="2025-10-07T17:48:33Z">
  <state datetime="2023-09-18">REFERRED</state>
  <status>
    <introduced datetime="2023-09-18"/>
  </status>
  <introduced datetime="2023-09-18"/>
  <titles>
    <title type="display">Maintaining Investments in New Innovation Act</title>
    <title type="short" as="introduced">Maintaining Investments in New Innovation Act</title>
    <title type="official" as="introduced">To amend title XI of the Social Security Act to protect access to genetically targeted technologies.</title>
  </titles>
  <sponsor bioguide_id="N000194"/>
  <cosponsors>
    <cosponsor bioguide_id="A000372" joined="2024-02-23"/>
    <cosponsor bioguide_id="B001260" joined="2024-05-01"/>
    <cosponsor bioguide_id="B001275" joined="2023-11-30"/>
    <cosponsor bioguide_id="B001248" joined="2024-08-27"/>
    <cosponsor bioguide_id="C000059" joined="2024-12-05"/>
    <cosponsor bioguide_id="C001126" joined="2024-05-15"/>
    <cosponsor bioguide_id="C001127" joined="2024-05-23"/>
    <cosponsor bioguide_id="C001120" joined="2023-11-14"/>
    <cosponsor bioguide_id="D000230" joined="2023-09-18"/>
    <cosponsor bioguide_id="D000628" joined="2024-09-10"/>
    <cosponsor bioguide_id="F000465" joined="2023-12-11"/>
    <cosponsor bioguide_id="G000583" joined="2024-09-10"/>
    <cosponsor bioguide_id="H001086" joined="2024-03-01"/>
    <cosponsor bioguide_id="H001082" joined="2024-10-29"/>
    <cosponsor bioguide_id="H001067" joined="2023-12-06"/>
    <cosponsor bioguide_id="J000302" joined="2023-09-18"/>
    <cosponsor bioguide_id="K000376" joined="2024-05-23"/>
    <cosponsor bioguide_id="M000317" joined="2024-04-10"/>
    <cosponsor bioguide_id="M001204" joined="2024-03-19"/>
    <cosponsor bioguide_id="M001215" joined="2024-03-21"/>
    <cosponsor bioguide_id="M001213" joined="2024-03-19"/>
    <cosponsor bioguide_id="M001206" joined="2024-12-05"/>
    <cosponsor bioguide_id="P000608" joined="2023-11-01"/>
    <cosponsor bioguide_id="P000048" joined="2024-10-29"/>
    <cosponsor bioguide_id="S001172" joined="2024-03-19"/>
    <cosponsor bioguide_id="S001199" joined="2024-06-14"/>
    <cosponsor bioguide_id="T000478" joined="2024-09-10"/>
    <cosponsor bioguide_id="V000134" joined="2024-05-15"/>
  </cosponsors>
  <actions>
    <action datetime="2023-09-18">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-09-18" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2023-09-18">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2023-09-22">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2024-12-17">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referred To"/>
    <committee code="HSWM02" name="House Ways and Means" subcommittee="Health" activity="Referral"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referred To"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="118" type="s" number="476" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Genetics"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2023-10-20T19:10:50Z" status="Introduced in House">Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare &amp; Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)</summary>
</bill>
